Efficacy of Glucocorticoids in the Treatment of Retinal Detachment With Choroidal Detachment: Analysis by Proteomics.

IF 2.1 4区生物学 Q3 BIOCHEMICAL RESEARCH METHODS

PROTEOMICS – Clinical Applications Pub Date : 2025-04-21 DOI:10.1002/prca.70008

Pingping Li, Mengyao Han, Rui Zhang, Fangyu Chen, Yanzi Li, Jing Yuan, Ning Ma, Lu Li, Jianhua Wu

{"title":"Efficacy of Glucocorticoids in the Treatment of Retinal Detachment With Choroidal Detachment: Analysis by Proteomics.","authors":"Pingping Li, Mengyao Han, Rui Zhang, Fangyu Chen, Yanzi Li, Jing Yuan, Ning Ma, Lu Li, Jianhua Wu","doi":"10.1002/prca.70008","DOIUrl":null,"url":null,"abstract":"Purpose: Glucocorticoids are widely used for their anti-inflammatory properties, but their specific molecular mechanisms in treating rhegmatogenous retinal detachment with choroidal detachment (RRDCD) remain unclear. This study aims to identify key regulatory factors in the vitreous humor of RRDCD patients and analyze protein changes after hormonal intervention.Methods: Vitreous fluid samples were collected during surgery from patients with rhegmatogenous retinal detachment (RRD, n = 40), non-glucocorticoid treated RRDCD (nT-RRDCD, n = 35), and glucocorticoid-treated RRDCD (T-RRDCD, n = 32). Primary outcomes were retinal reattachment status and best-corrected visual acuity (BCVA) at 6 months postoperatively. Proteomic analysis was performed using data-independent acquisition (DIA), with differentially expressed proteins validated by parallel reaction monitoring (PRM) and ELISA.Results: Between RRD and nT-RRDCD, 203 differentially expressed proteins were identified, while 295 proteins were differentially expressed between nT-RRDCD and T-RRDCD. These proteins were involved in complement activation, immune response, blood coagulation, and MAPK signaling. Apolipoprotein D (APOD) and vitronectin (VTN) positively correlated with postoperative BCVA. APOD, serum amyloid A-4 (SAA4), and ubiquitin-conjugating enzyme E2 variant emerged as potential diagnostic biomarkers for RRDCD.Conclusions: RRDCD development involves multiple factors. Glucocorticoids mitigate retinal damage by suppressing inflammation, regulating oxidative stress, and promoting cell repair. APOD and VTN correlate with BCVA, while APOD, SAA4, and ubiquitin-conjugating enzyme E2 show promise as diagnostic biomarkers for RRDCD.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e70008"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.70008","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Glucocorticoids are widely used for their anti-inflammatory properties, but their specific molecular mechanisms in treating rhegmatogenous retinal detachment with choroidal detachment (RRDCD) remain unclear. This study aims to identify key regulatory factors in the vitreous humor of RRDCD patients and analyze protein changes after hormonal intervention.

Methods: Vitreous fluid samples were collected during surgery from patients with rhegmatogenous retinal detachment (RRD, n = 40), non-glucocorticoid treated RRDCD (nT-RRDCD, n = 35), and glucocorticoid-treated RRDCD (T-RRDCD, n = 32). Primary outcomes were retinal reattachment status and best-corrected visual acuity (BCVA) at 6 months postoperatively. Proteomic analysis was performed using data-independent acquisition (DIA), with differentially expressed proteins validated by parallel reaction monitoring (PRM) and ELISA.

Results: Between RRD and nT-RRDCD, 203 differentially expressed proteins were identified, while 295 proteins were differentially expressed between nT-RRDCD and T-RRDCD. These proteins were involved in complement activation, immune response, blood coagulation, and MAPK signaling. Apolipoprotein D (APOD) and vitronectin (VTN) positively correlated with postoperative BCVA. APOD, serum amyloid A-4 (SAA4), and ubiquitin-conjugating enzyme E2 variant emerged as potential diagnostic biomarkers for RRDCD.

Conclusions: RRDCD development involves multiple factors. Glucocorticoids mitigate retinal damage by suppressing inflammation, regulating oxidative stress, and promoting cell repair. APOD and VTN correlate with BCVA, while APOD, SAA4, and ubiquitin-conjugating enzyme E2 show promise as diagnostic biomarkers for RRDCD.

查看原文本刊更多论文

糖皮质激素治疗视网膜脱离合并脉络膜脱离的疗效：蛋白质组学分析。

目的：糖皮质激素因其抗炎特性而被广泛应用，但其在治疗孔源性视网膜脱离合并脉络膜脱离（RRDCD）中的具体分子机制尚不清楚。本研究旨在确定RRDCD患者玻璃体幽默的关键调控因子，并分析激素干预后蛋白的变化。方法：术中采集孔源性视网膜脱离（RRD, n = 40）、非糖皮质激素治疗的RRDCD （nT-RRDCD, n = 35）和糖皮质激素治疗的RRDCD （T-RRDCD, n = 32）患者的玻璃体液标本。主要结果为术后6个月视网膜再附着状态和最佳矫正视力（BCVA）。采用数据独立采集（DIA）进行蛋白质组学分析，通过平行反应监测（PRM）和ELISA验证差异表达蛋白。结果：在RRD和nT-RRDCD之间鉴定到203个差异表达蛋白，在nT-RRDCD和T-RRDCD之间鉴定到295个差异表达蛋白。这些蛋白参与补体激活、免疫反应、血液凝固和MAPK信号传导。载脂蛋白D （APOD）和玻璃体粘连蛋白（VTN）与术后BCVA呈正相关。APOD、血清淀粉样蛋白A-4 （SAA4）和泛素偶联酶E2变异体被认为是RRDCD的潜在诊断生物标志物。结论：RRDCD的发展涉及多种因素。糖皮质激素通过抑制炎症、调节氧化应激和促进细胞修复来减轻视网膜损伤。APOD和VTN与BCVA相关，而APOD、SAA4和泛素偶联酶E2有望作为RRDCD的诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PROTEOMICS – Clinical Applications 医学-生化研究方法

CiteScore

5.20

自引率

5.00%

发文量

审稿时长

1 months

期刊介绍： PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.